BACKGROUND & AIMS: The transcription factor nuclear factor-kappaB (NF)-kappaB promotes survival of hepatic myofibroblasts and fibrogenesis through poorly defined mechanisms. We investigated the activities of angiotensin II and I kappaB kinase (IKK) in regulation of NF-kappaB activity and the role of these proteins in liver fibrosis in rodents and humans. METHODS: Phosphorylation of the NF-kappaB subunit RelA at serine 536 (P-Ser(536)-RelA) was detected by immunoblot and immunohistochemical analyses. P-Ser(536)-RelA function was assessed using vectors that expressed mutant forms of RelA, cell-permeable blocking peptides, and assays for RelA nuclear transport and apoptosis. Levels of P-Ser(536)-RelA were compared with degree of fibrosis in liver sections from chronically injured rats and patients with hepatitis C virus-mediated fibrosis who had been treated with the AT1 antagonist losartan. RESULTS: Constitutive P-Ser(536)-RelA is a feature of human hepatic myofibroblasts, both in vitro and in situ in diseased livers. Autocrine angiotensin II stimulated IKK-mediated phosphorylation of RelA at Ser(536), which was required for nuclear transport and transcriptional activity of NF-kappaB. Inhibition of angiotensin II, the angiotensin II receptor type 1 (AT1), or IKK blocked Ser(536) phosphorylation and stimulated myofibroblast apoptosis. Treatment of fibrotic rodent liver with the angiotensin converting enzyme (ACE) inhibitor captopril or the IKK inhibitor sulphasalazine resulted in loss of P-Ser(536)-RelA-positive myofibroblasts and fibrosis regression. In human liver samples, increased numbers of P-Ser(536)-RelA-positive cells were associated with fibrosis that regressed following exposure to losartan. CONCLUSIONS: An autocrine pathway that includes angiotensin II, IKK, and P-Ser(536)-RelA regulates myofibroblast survival and can be targeted to stimulate therapeutic regression of liver fibrosis.
BACKGROUND & AIMS: The transcription factor nuclear factor-kappaB (NF)-kappaB promotes survival of hepatic myofibroblasts and fibrogenesis through poorly defined mechanisms. We investigated the activities of angiotensin II and I kappaB kinase (IKK) in regulation of NF-kappaB activity and the role of these proteins in liver fibrosis in rodents and humans. METHODS: Phosphorylation of the NF-kappaB subunit RelA at serine 536 (P-Ser(536)-RelA) was detected by immunoblot and immunohistochemical analyses. P-Ser(536)-RelA function was assessed using vectors that expressed mutant forms of RelA, cell-permeable blocking peptides, and assays for RelA nuclear transport and apoptosis. Levels of P-Ser(536)-RelA were compared with degree of fibrosis in liver sections from chronically injured rats and patients with hepatitis C virus-mediated fibrosis who had been treated with the AT1 antagonist losartan. RESULTS: Constitutive P-Ser(536)-RelA is a feature of human hepatic myofibroblasts, both in vitro and in situ in diseased livers. Autocrine angiotensin II stimulated IKK-mediated phosphorylation of RelA at Ser(536), which was required for nuclear transport and transcriptional activity of NF-kappaB. Inhibition of angiotensin II, the angiotensin II receptor type 1 (AT1), or IKK blocked Ser(536) phosphorylation and stimulated myofibroblast apoptosis. Treatment of fibrotic rodent liver with the angiotensin converting enzyme (ACE) inhibitor captopril or the IKK inhibitor sulphasalazine resulted in loss of P-Ser(536)-RelA-positive myofibroblasts and fibrosis regression. In human liver samples, increased numbers of P-Ser(536)-RelA-positive cells were associated with fibrosis that regressed following exposure to losartan. CONCLUSIONS: An autocrine pathway that includes angiotensin II, IKK, and P-Ser(536)-RelA regulates myofibroblast survival and can be targeted to stimulate therapeutic regression of liver fibrosis.
Authors: Yun Dai; Shuang Chen; Li Wang; Xin-Yan Pei; Vanessa L Funk; Lora B Kramer; Paul Dent; Steven Grant Journal: J Biol Chem Date: 2011-08-04 Impact factor: 5.157
Authors: Michaela Granzow; Robert Schierwagen; Sabine Klein; Benita Kowallick; Sebastian Huss; Markus Linhart; Irela G Reza Mazar; Jan Görtzen; Annabelle Vogt; Frank A Schildberg; Maria A Gonzalez-Carmona; Alexandra Wojtalla; Benjamin Krämer; Jacob Nattermann; Sören V Siegmund; Nikos Werner; Dieter O Fürst; Wim Laleman; Percy Knolle; Vijay H Shah; Tilman Sauerbruch; Jonel Trebicka Journal: Hepatology Date: 2014-05-06 Impact factor: 17.425
Authors: Laurie D DeLeve; Hartmut Jaeschke; Vijay K Kalra; Kinji Asahina; David A Brenner; Hidekazu Tsukamoto Journal: Liver Int Date: 2011-04-19 Impact factor: 5.828
Authors: Johannes Kluwe; Jean-Philippe Pradere; Geum-Youn Gwak; Ali Mencin; Samuele De Minicis; Christoph H Osterreicher; Jordi Colmenero; Ramon Bataller; Robert F Schwabe Journal: Gastroenterology Date: 2009-09-24 Impact factor: 22.682
Authors: Veronika Souslova; Paul A Townsend; Jelena Mann; Chris M van der Loos; Anna Motterle; Fulvio D'Acquisto; Derek A Mann; Shu Ye Journal: PLoS One Date: 2010-03-25 Impact factor: 3.240